Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 08 2021 - 8:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that Todd C. Brady, M.D., Ph.D., President and Chief
Executive Officer, will participate in a fireside chat at the H.C.
Wainwright BioConnect 2021 Virtual Conference.
The fireside chat will be available beginning at 6:00 a.m. ET
Monday, January 11, 2021 on the Investors & Media section of
the Aldeyra Therapeutics website at https://ir.aldeyra.com. The
event will remain archived on the website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead investigational compounds, reproxalap and
ADX-629, target RASP (reactive aldehyde species), which are
elevated in ocular and systemic inflammatory disease and result in
cytokine release via activation of a broad array of inflammatory
factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Reproxalap is being evaluated in Phase 3 clinical trials in
patients with dry eye disease and allergic conjunctivitis. The
company’s clinical pipeline also includes ADX-2191, a dihydrofolate
reductase inhibitor in Phase 3 testing for proliferative
vitreoretinopathy, and ADX-1612, a chaperome inhibitor in
development for COVID-19 and ovarian cancer. For more information,
visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook,
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210108005281/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024